Trial Profile

A study assessing Zofin for heart failure with preserved ejection fraction

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zofin (Primary)
Indications Heart failure
Focus Therapeutic Use
Sponsors ZEO ScientifiX

Most Recent Events

04 Mar 2024 According to a ZEO ScientifiX, Inc media release, company name changed from Organicell to ZEO ScientifiX.
27 Oct 2020 New trial record
20 Oct 2020 According to an Organicell media release, the company plans to collaborate with Regenerative Care Network (RCN) . This collaboration will focus on the conduct of clinical trials to take place at various medical institutions in Dallas and Houston, as soon as possible after an Investigational New Drug Application (IND) is filed with and approved by the FDA and Institutional Review Board (IRB) approval is received. Dr. Friedewald is expected to be the principal investigator for this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com